Fig. 1From: Development of OXY111A, a novel hypoxia-modifier as a potential antitumor agent in patients with hepato-pancreato-biliary neoplasms - Protocol of a first Ib/IIa clinical trialEffects of hypoxia in HPB tumorsBack to article page